Novel treatments for progressive multifocal leukoencephalopathy
| Autor: | Karina Bennett, Peter M Fernandes |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Filgrastim T cell Programmed Cell Death 1 Receptor Pembrolizumab Antibodies Monoclonal Humanized Leukoencephalopathy Immunocompromised Host 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Immune system medicine Humans 030212 general & internal medicine Demyelinating Disorder Aged business.industry Progressive multifocal leukoencephalopathy Leukoencephalopathy Progressive Multifocal General Medicine medicine.disease JC Virus Nivolumab medicine.anatomical_structure Immunology business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Bennett, K M & Fernandes, P M 2020, ' Novel treatments for progressive multifocal leukoencephalopathy ', British journal of hospital medicine, vol. 81, no. 7, pp. 1-9 . https://doi.org/10.12968/hmed.2020.0093 |
| DOI: | 10.12968/hmed.2020.0093 |
| Popis: | Progressive multifocal leukoencephalopathy is a rare demyelinating disorder of the CNS, caused by John Cunningham virus, that occurs in those with impaired immune systems. Existing treatment options are ineffective or unproven. This article reviews research into novel therapies: immune checkpoint-blocking antibodies (nivolumab and pembrolizumab), allogenic BK virus-specific T cell treatment and filgrastim. Results for these therapies in small clinical trials are promising, but further research is required to assess efficacy fully. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|